Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359732 | 1.00 | CCR2 (0.78) | CCR2KCNH2 | |
| SCHEMBL1360685 | 1.00 | CCR2 (0.78) | CCR2KCNH2 | |
| SCHEMBL744949 | 0.91 | CCR2 (0.79) | CCR2KCNH2 | |
| SCHEMBL744948 | 0.91 | CCR2 (0.79) | CCR2KCNH2 | |
| SCHEMBL765263 | 0.91 | CCR2 (0.79) | CCR2KCNH2 | |
| SCHEMBL1361444 | 0.88 | CCR2 (0.66) | CCR2KCNH2 | |
| SCHEMBL11994965 | 0.88 | CCR2 (0.66) | CCR2KCNH2 | |
| SCHEMBL745071 | 0.88 | CCR2 (0.92) | CCR2KCNH2 | |
| SCHEMBL745070 | 0.88 | CCR2 (0.92) | CCR2KCNH2 | |
| SCHEMBL743948 | 0.87 | CCR2 (0.90) | CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214807-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8067457-B2 | Compounds useful as antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090197884-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214807-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | CCR2, CCR1, CXCR3 | CCR2 1/4885KCNH2 2318/4885 |
| US-20090197884-A1 | Compounds Useful as Antagonists of CCR2 | CCR2, CCR1, CXCR3 | CCR2 1/4885KCNH2 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.